A phase IIIb study in the United States that evaluated Dovato (dolutegravir/lamivudine) for rapid initiation of treatment after diagnosis in adults with HIV-1 found the medicine to be effective and well tolerated in the setting, indicating the feasibility of its use in Test and Treat strategies.

Pixium Vision announced that the bioelectronics company’s subretinal PRIMA system met the endpoints of the feasibility study, at interim 6 months follow-up after implantation and rehabilitation for patients with advanced dry age-related macular degeneration (AMD).